PROM1 and rhabdomyosarcoma: Many studies have investigated whether CD133 expression is useful for clinical outcomes, and these studies have shown that CD133 is positively related to poor prognosis in HCC patients [14], that high CD133 levels are associated with shorter survival rates in rhabdomyosarcoma patients [15], and that CD133 expression might be an unfavorable prognosis for ovarian cancer patients [16].